CD4 and psoriasis: Notably, baseline levels of Th17 and Tc17 cells, as well as LAG-3 expression on CD4<sup>+</sup> and CD8<sup>+</sup> T cells, were higher in non-early responders than in early responders.<h4>Conclusion</h4>Ixekizumab treatment may restore immune dysregulation in psoriasis patients.